General model | All participants (n = 28) | Patient Association (n = 4) | Physicians (n = 6) | Health economics (n = 7) | Hospital pharmacy (n = 5) | Health Authorities (n = 6) | |||||
---|---|---|---|---|---|---|---|---|---|---|---|
Beta (coefficient) | Standard error | Z-value | p. value | Odds ratio | Rel. Imp (%) | Rel. Imp (%) | Rel. Imp (%) | Rel. Imp (%) | Rel. Imp | Rel. Imp (%) | |
HRQoL | − 1.011 | 0.069 | − 14.742 | < 0.001 | 0.364 | 23.53 | 14.27 | 20.55 | 25.11 | 22.35 | 21.83 |
Efficacy | − 0.614 | 0.067 | − 9.175 | < 0.001 | 0.541 | 14.64 | 13.23 | 15.05 | 8.86 | 17.70 | 10.73 |
Availability of treatment alternatives | − 0.552 | 0.065 | − 8.466 | < 0.001 | 0.576 | 13.51 | 11.00 | 9.92 | 6.00 | 16.43 | 19.39 |
Disease severity | 0.514 | 0.065 | 7.907 | < 0.001 | 1.672 | 12.62 | 13.93 | 11.62 | 14.82 | 8.89 | 5.27 |
Avoided costs | − 0.452 | 0.064 | − 7.020 | < 0.001 | 0.636 | 11.21 | 11.55 | 10.45 | 13.06 | 9.27 | 6.90 |
Age of target population | − 0.499 | 0.103 | − 4.854 | < 0.001 | 0.607 | 7.75 | 6.55 | 8.20 | 2.15 | 8.22 | 10.16 |
Safety (seriousness of AE) | − 0.303 | 0.103 | − 2.956 | 0.003 | 0.738 | 4.72 | 8.70 | 5.49 | 4.15 | 1.50 | 1.10 |
Quality of evidence | − 0.151 | 0.063 | − 2.392 | 0.017 | 0.860 | 3.82 | 3.91 | 7.21 | 2.44 | 4.50 | 1.05 |
Target population | − 0.125 | 0.064 | − 1.952 | 0.051* | 0.883 | 3.12 | 2.62 | 0.38 | 2.13 | 3.61 | 7.26 |
Economic burden of the disease | 0.103 | 0.065 | 1.568 | 0.117 | 1.108 | 2.50 | 3.15 | 3.78 | 2.97 | 2.43 | 2.78 |
Cost of treatment | 0.072 | 0.066 | 1.086 | 0.278 | 1.074 | 1.73 | 2.34 | 2.57 | 4.72 | 0.79 | 4.88 |
Cost-effectiveness | − 0.054 | 0.103 | − 0.518 | 0.604 | 0.948 | 0.83 | 7.57 | 2.83 | 9.46 | 2.04 | 6.15 |
Safety (AE frequency) | − 0.002 | 0.103 | − 0.017 | 0.986 | 0.998 | 0.03 | 1.19 | 1.73 | 4.12 | 2.25 | 2.52 |